Molecular biomaterial engineering permits in vivo transplantation of cells and tissues, offering the promise of restoration of physiologic control rather than pharmacologic dosing with isolated compounds. We engrafted endothelial cells on Gelfoam biopolymeric matrices with retention of viability, normal growth kinetics, immunoreactivity, and biochemical activity. The production of heparan sulfate proteoglycan and inhibition of basic fibroblast growth factor binding and activity by engrafted cells were indistinguishable from endothelial cells grown in culture. Perivascular implantation of Gelfoam-endothelial cell scaffolds around balloon-denuded rat carotid arteries reduced intimal hyperplasia 88.1%, far better than the isolated administration of heparin, the most effective endothelial mimic compound. In concert with a reduction in intimal area, cell proliferation was reduced by > 90%.
sulfate proteoglycan and inhibition of basic fibroblast growth factor binding and activity by engrafted cells were indistinguishable from endothelial cells grown in culture. Perivascular implantation of Gelfoam-endothelial cell scaffolds around balloon-denuded rat carotid arteries reduced intimal hyperplasia 88.1%, far better than the isolated administration of heparin, the most effective endothelial mimic compound. In concert with a reduction in intimal area, cell proliferation was reduced by > 90%. To our knowledge, there have been no previous reports of extravascular cell implants controlling vasculoproliferative disease. Tissue engineered cells offer the potential for potent methods of vascular growth regulation and insight into the complex autocrine-paracrine control mechanisms within the blood vessel wall.
Though the hallmark of the accelerated arteriopathies that follow angioplasty and vascular bypass grafting is the proliferation of smooth muscle cells and their accumulation within the tunica intima, it is the loss of normal endothelial function that heralds these events and may stimulate them to occur (1, 2) . The arterial endothelium serves as a transport barrier, a biochemical filter, and a regulator of many vascular phenomena. The most potent vasodilators, thromboresistant compounds and inhibitors of smooth muscle cell proliferation, are endothelially derived. Vascular smooth muscle cell accumulation within the intima ceases with restoration of the endothelium (3, 4) and regression of intimal hyperplasia is maximized where endothelial restoration is maximized (5) . Autologous endothelial cell transplantation (6) (7) (8) and implantation of endothelial cell-seeded interposition grafts (9, 10) or endovascular stents (11) have repopulated the surface of denuded arteries. These approaches may recreate the endothelial barrier. However, inhibition of intimal hyperplasia has yet to be demonstrated, perhaps because contact with circulating blood limits the efficiency and duration of cell seeding (6) (7) (8) (9) (10) (11) (12) . Moreover, it is not clear that the endothelial control ofvascular injury and smooth muscle cell proliferation requires that the endothelial cells reside at the luminal interface. The biochemical regulation imposed by the endothelium may be equipotent to or of far greater importance than its barrier function and may be active even if these cells are at a distance from the lumen.
To address this question we engrafted cells on threedimensional biopolymeric scaffoldings and placed them in the perivascular space of denuded blood vessels. Engrafted endothelial cells remained viable in large numbers within matrices of the porous collagen-like Gelfoam material, with full retention of their biologic activity and the biochemical markers of normal vascular cells. More importantly, though the perivascular space is significantly distant from the denuded intimal/ luminal interface, cells implanted in the perivascular area inhibited intimal hyperplasia to a greater extent than any other intervention and without the need for restoration of the endothelial luminal barrier. The desired density of cells can be established in vitro and implanted in vivo within the protected environment of the biopolymer scaffolding. Tissue engineered perivascular cell implantation may, therefore, allow us to examine fundamental issues in vascular biology, such as the regulatory role of the endothelium, and to develop alternative therapies for vascular injury.
MATERIALS AND METHODS
Cell Engraftment. Gelfoam has long been used as an implantable surgical sponge and more recently as a scaffolding for cell growth (13) . This material, isolated from porcine dermal gelatin, was supplied in blocks (Upjohn) and cut into 2.5 x 1.0 x 0.3 cm pieces and hydrated by autoclaving for 10 min in Hanks' balanced salt solution (HBSS 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. these points in time by trypan blue exclusion. The preservation of the immune identity of cells within Gelfoam blocks recovered 14 days after placement in tissue culture or around rat carotid arteries was determined by immunostaining for the endothelial marker von Willebrand factor as described in detail (16) .
Proteoglycan Production. The amount of heparan sulfate in conditioned medium produced by cells cultured on Gelfoam or tissue culture polystyrene was measured. Gelfoam films containing endothelial cells or CHO-745 cells were incubated in culture medium containing no antibiotics and no calf serum for 24 hr at 37°C. As a control, identical Gelfoam films without cells were incubated in the same media. The medium was collected, centrifuged (5000 x g), dialyzed exhaustively against water, and concentrated by lyophilization. Total sulfated glycosaminoglycan was determined using dimethylmethylene blue (17) , and the amount of heparan sulfate was assessed after samples were treated with heparinase. The endothelial and CHO-745 cells grown on Gelfoam were also radiolabeled with 35S04 (100 ,uCi/ml, 24 hr; 1 Ci = 37 GBq) to visualize the metabolic synthesis of heparan sulfate by the cells. The medium was collected and centrifuged, and the 35SO4-proteoglycan was separated from the free 35S04 by vacuum filtration through cationic nylon membranes (18) . Filters containing 35S04-proteoglycan were incubated in nitrous acid (0.45 M sodium nitrite combined with 3.6 M acetic acid) and counted to determine the amount of radioactivity incorporated within heparan sulfate.
Biologic Effect. The biologic effects of cell engrafts were tested in culture and in vivo. The ability of conditioned medium from endothelial cell-and CHO-745 cell-Gelfoam to block bFGF-induced smooth muscle cell mitogenesis and 125I-labeled bFGF (125I-bFGF) binding to heparan sulfate proteoglycan of confluent, quiescent vascular smooth muscle cell monolayers was determined (14) . In vivo potency was assessed by evaluating the ability of Gelfoam (2.5 x 1.0 x 0.3 cm each) containing endothelial cells, CHO-745 cells, or no cells, to alter intimal hyperplasia when wrapped around endothelial denuded rat common carotid arteries (16, 19, 20) . The strip ends overlapped, ensuring complete encircling of the artery. Fascial planes were sutured closed to further immobilize the device. To compare the results of anticipated physiologic secretion of endothelial cell products to the pharmacologic dosing of a proven endothelial-cell analog, hydrogel films were formulated (21) to release heparin alone at a dose, 2.5 ± 0.1 ,ug/day, similar to the daily release of heparan sulfate proteoglycan from the engrafted cells (1.2 ± 0.1 ,ug/day). This dose and mode of delivery have previously been demonstrated to maximize heparin's inhibition of neointimal hyperplasia (20, 22, 23) .
On the 14th postoperative day, animals were euthanized and perfused clear via the left ventricle with Ringer's lactate solution followed by immersion fixation with Carnoy's fixative (60% methanol/30% chloroform/10% glacial acetic acid).
The location of the implanted films was marked with India ink, and the films were recovered with the entire length of the intact arteries. The carotid arteries were harvested and cut into five equal segments, three including the Gelfoam wrap and one segment each above and below the wraps. Segments were paraffin embedded and 6-,um sections were obtained along the length of each segment. After staining with hematoxylin/eosin or verHoeff's elastin stain, the intimal, medial, and adventitial areas, the intima:media area ratio (I:M) and the percent of luminal occlusion were calculated using computerized digital planimetry with a dedicated video microscope and customized software. Cell proliferation was assayed using immunocytochemical identification of the thymidine analog 5-bromo-2'-deoxyuridine (BrdUrd), which had been injected intraperitoneally, at 50 mg/kg, 3 and 7 days after surgery and 1 hr prior to sacrifice (16, (22) (23) (24) .
Statistical comparisons were performed using analysis of variance (ANOVA) and subsequent differences among groups using Student's t test. Data were rejected as not significantly different if P values of >0.05 were observed. Data line fits were established using a linear regression and correlation model.
RESULTS
Growth Kinetics, Immunologic Identification, and Biochemical Activity ofEngrafted Cells. Bovine aortic endothelial cells, and mutant CHO cells (CHO-745) were cultured in Gelfoam matrices. Engrafted cells lined the interstices of the three-dimensional collagen-like Gelfoam matrix (13) and followed a growth pattern similar to that observed for cells harvested from intact blood vessels and cultured on polystyrene (Fig. 1) . Cell viability, as evaluated by trypan blue exclusion, remained at 90% ± 2.3% for the endothelial cells and 93.1% ± 1.7% for the CHO-745 cells over the 15-day culture course. The preservation of the immune identity of the implanted cells was documented when Gelfoam implants with endothelial cells were recovered 14 days after placement around the common carotid artery of laboratory animals. Immunostaining for the endothelial marker von Willebrand factor in the engrafted cells was unchanged from primary cultured cells ( Fig. 1 b and c) .
Engrafted cells remained viable with full retention of biochemical secretory ability and biologic potency as well as immunoidentity. Cells cultured on Gelfoam produced nearly identical amounts of total sulfated glycosaminoglycan and heparan sulfate as that produced when the same cells were grown on polystyrene dishes. In addition, there was no significant difference in the profile of the proteoglycan when resolved on 5% SDS/PAGE. For (Fig. 2) (14) . In contrast, conditioned medium from CHO-745 cells had no effect on binding and, similarly, no effect on growth factor-induced mitogenesis, as expected (Fig. 2) .
Engrafted Cell Implants Inhibit Intimal Hyperplasia and Cell Proliferation. The in vivo potency of the endothelial cell engrafts was retained in addition to their in vitro effects. Balloon denudation of the carotid arterial endothelium led to an increase in the ratio of the area of the tunica intima to the area of the tunica media (I:M) to 1.44 ± 0. 16 (Fig. 3) ating cells relative to the total number of cells in the tunicae media and intima were used as indices of proliferation. Gelfoam implants with engrafted endothelial cells caused a statistically significant decrease in cell proliferation in the tunica intima (29.4% reduction) and tunica media (26.3% reduction) relative to empty Gelfoam implants (Fig. 3e) . Heparin infusion also decreased proliferation but the effect was not statistically significant at the number of animals and sections examined. Relative to balloon injury alone, heparin administration reduced BrdUrd immunostaining in the tunica intima by 11.0% and by 12.2% in the tunica media (Fig. 3e) .
There was no evidence that the implants induced cellular or systemic rejection. The general health and appearance of the animals with the Gelfoam implants were unchanged from controls. Rats subjected to balloon injury alone gained 52.9 ± 3.6 g over the 14-day experimental period, and those animals that received a cell-free Gelfoam implant hydrated in either DMEM or Ham's F-12 medium gained 48.0 ± 7.3 g. The animals implanted with endothelial-seeded implants gained 51.3 ± 2.8 g and the animals with CHO-745-laden Gelfoam gained 53.4 ± 6.5 g. Rats receiving perivascular heparin gained 56.7 ± 6.2 g.
DISCUSSION
Endothelial Regulation of Vascular Biology. Arterial endothelial cells form a continuous, selectively permeable, nonthrombogenic barrier between circulating blood and the arterial wall that controls many facets of vascular biology (1, 2). The anatomic continuity of the endothelial monolayer and the underlying vascular smooth muscle cells provides biochemical control of vascular physiology as well as structural integrity. Endothelial-derived products control blood flow and vessel tone (30, 31) , thrombosis, platelet activation, adhesion and aggregation (32, 33) , leukocyte adhesion (34-37), monocyte infiltration and smooth muscle cell migration (38, 39) , and proliferation (3, 14, 19, 26, 29, (40) (41) (42) . The homeostatic set point that determines the steady-state conditions for all of these parameters maintains the normal blood vessel in a quiescent state. Endothelial loss or dysfunction leads to an alteration in this balance and sets in place a sequence of events that culminates in the proliferation of normally quiescent smooth muscle cells. Restoration of the endothelium inhibits smooth muscle cell accumulation after denuding arterial injury (3, 4) , and stimulation of endothelial restoration simultaneously maximizes regression of intimal hyperplasia (5) . Yet, it is still not evident which of the many functions of the endothelium are required to reconstruct homeostasis. Nor do we understand why the infusion of analogs of endothelial products such as heparin (3, 14, 19, 25-29 Heparin reduced cell proliferation relative to balloon-injured arterial controls by 11% within the tunica intima (23.1% ± 3.0%) and the tunica media by 12.2% (8.4% ± 2.1%), and the engrafted endothelial cells were 2.2-fold more effective in the tunica intima (29 (Fig. 2) . Similarly, only endothelial cell engrafts inhibited intimal hyperplasia (Fig. 3) . Gelfoam alone or seeded with CHO-745 cells had no statistically significant effect on cell proliferation or intimal hyperplasia. Heparin is one of the most effective antiproliferative agents for vascular smooth muscle cells (3, 14, 19, (25) (26) (27) (28) (29) . Yet, when this drug was released at twice the rate of heparan sulfate proteoglycan production by the endothelial cells, intimal hyperplasia (Fig. 3d ) and smooth muscle cell proliferation (Fig. 3e) were also reduced but 3.2-fold less effectively than with the endothelial cell engrafts.
The control exerted by the endothelial cell implants appears to result solely from the biochemical effects of the engrafted cells. Immunostaining with endothelial cell-specific markers detected no evidence for early recovery of endogenous endothelial cells or the migration of engrafted cells from their biopolymer scaffoldings to the arterial lining in any of the recovered arterial segments. The effects of the engrafts were localized in a similar manner to the focal effects observed with the perivascular release of other compounds (16, 20, 44) . There was no evidence of a systemic or local immune response or graft rejection that might alternatively explain the results.
Thus, it appears that endothelial control of vascular proliferation stems in large part from biochemical regulation rather than mechanical barrier function and that the combined secretion of many compounds at physiologic doses by the intact cell is superior to pharmacologic administration of isolated endothelial cell-derived products. It is hoped that additional work with species-specific cells, novel polymer materials, and genetically modified cells with regulated secretory activity will enhance further the therapeutic and research potential of this approach.
